Browse FDX1

Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix
Domain PF00111 2Fe-2S iron-sulfur cluster binding domain
Function

Essential for the synthesis of various steroid hormones (PubMed:20547883, PubMed:21636783). Participates in the reduction of mitochondrial cytochrome P450 for steroidogenesis (PubMed:20547883, PubMed:21636783). Transfers electrons from adrenodoxin reductase to CYP11A1, a cytochrome P450 that catalyzes cholesterol side-chain cleavage (PubMed:20547883, PubMed:21636783). Does not form a ternary complex with adrenodoxin reductase and CYP11A1 but shuttles between the two enzymes to transfer electrons (By similarity).

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006694 steroid biosynthetic process
GO:0006700 C21-steroid hormone biosynthetic process
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0008207 C21-steroid hormone metabolic process
GO:0010817 regulation of hormone levels
GO:0016125 sterol metabolic process
GO:0034754 cellular hormone metabolic process
GO:0042445 hormone metabolic process
GO:0042446 hormone biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1902652 secondary alcohol metabolic process
Molecular Function GO:0005506 iron ion binding
GO:0009055 electron carrier activity
GO:0051536 iron-sulfur cluster binding
GO:0051537 2 iron, 2 sulfur cluster binding
GO:0051540 metal cluster binding
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-211859: Biological oxidations
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-5579026: Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
R-HSA-1643685: Disease
R-HSA-5668914: Diseases of metabolism
R-HSA-2395516: Electron transport from NADPH to Ferredoxin
R-HSA-211976: Endogenous sterols
R-HSA-5579029: Metabolic disorders of biological oxidation enzymes
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-196071: Metabolism of steroid hormones
R-HSA-1362409: Mitochondrial iron-sulfur cluster biogenesis
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-196108: Pregnenolone biosynthesis
R-HSA-209943: Steroid hormones
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FDX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FDX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FDX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1820.462
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0070.996
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3110.764
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3720.241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4940.691
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2250.872
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3710.285
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3550.789
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.430.776
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2370.836
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0090.996
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1760.0527
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FDX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FDX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FDX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FDX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FDX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FDX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFDX1
Nameferredoxin 1
Aliases ADX; adrenodoxin; FDX; LOH11CR1D; adrenal ferredoxin; ferredoxin-1; hepatoredoxin; mitochondrial adrenodoxin ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FDX1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FDX1.
ID Name Drug Type Targets #Targets
DB00648MitotaneSmall MoleculeAR, CYP11B1, ESR1, FDX1, PGR5